

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**(1) RESIGNATION OF  
INDEPENDENT NON-EXECUTIVE DIRECTOR AND  
CHANGE IN COMPOSITION OF BOARD COMMITTEES;  
AND  
(2) NON-COMPLIANCE WITH LISTING RULES**

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR  
AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The board (the “**Board**”) of the directors (the “**Director(s)**”) of PuraPharm Corporation Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that Mr. Ho Kwok Wah, George (“**Mr. Ho**”) has resigned as an independent non-executive Director, the chairman of the audit committee of the Board and a member of each of the remuneration committee and the nomination committee of the Board with effect from 4 July 2025 in order to devote more time to develop his personal and other business commitments.

Mr. Ho has confirmed that he has no disagreement with the Board and there is no matter regarding his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Ho for his invaluable contributions to the Company during his tenure of office as an independent non-executive Director.

## **NON-COMPLIANCE WITH THE LISTING RULES**

Following the resignation of Mr. Ho, the Board comprises of three executive Directors, one non-executive Director and two independent non-executive Directors. As a result of the foregoing, the Company is not in compliance with the requirements of (i) Rule 3.10(1) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) that the Board must include at least three independent non-executive Directors; (ii) Rule 3.10(2) of the Listing Rules that at least one of the independent non-executive directors must have appropriate professional qualifications or accounting or related financial management expertise; (iii) Rule 3.21 of the Listing Rules that the audit committee of the Board must comprise a minimum of three members and must be chaired by an independent non-executive director; (iv) Rule 3.25 of the Listing Rules that the remuneration committee of the Board must comprise a majority of independent non-executive directors; and (v) Rule 3.27A of the Listing Rules that the nomination committee comprises a majority of independent non-executive directors.

The Company is in the process of identifying suitable candidate(s) to fill the casual vacancy of independent non-executive Director, the member of each of the audit committee, the remuneration committee and the nomination committee of the Board in order to meet the aforementioned Listing Rules requirements, and will use its best endeavors to ensure a suitable candidate is appointed as soon as practicable, in any event within three months from the date hereof. Further announcement(s) will be made by the Company as and when appropriate.

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 4 July 2025

*As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Director is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors are Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*